RCS - Ondine Biomedical - ICU Study to be Presented at 2026 CACCN Conference

Ondine Biomedical

27/04/2026 07:00

RNS Number : 9410B

Ondine Biomedical Inc.

27 April 2026

 

27 April 2026

Ondine Biomedical Inc. ("Ondine" or the "Company")

Steriwave ICU Study Findings Selected for Oral Presentation at National Canadian Critical Care Nursing Conference

Ondine Biomedical Inc. (AIM: OBI), a global leader in light-activated antimicrobial therapies, announces that the intensive care unit ("ICU") infection study featuring Steriwave® nasal photodisinfection, published in Critical Care on 14 April 2026, has been accepted for both oral and poster presentation at the Canadian Critical Care Nursing Conference ("CACCNC"). This selection is expected to increase visibility and awareness of the study's findings, which provide new evidence supporting a non-antibiotic approach to reducing nasal pathogens associated with life-threatening infections in the ICU. 

The conference, the premier annual event for the Canadian Association of Critical Care Nurses ("CACCN"), will be held from 29-30 September 2026, at the Delta Prince Edward in Charlottetown, Prince Edward Island.

The accepted abstract, titled "Results of a crossover pilot study of nasal photo-disinfection demonstrating significant pathogen reduction in ICU patients", discusses the findings of the SMURF Feasibility Pilot Study conducted by AIM Royal Columbian Hospital Foundation and the role for nasal photodisinfection in ICU settings. This Canadian-based research, led by RCHF AIM's Dr Stephen Reynolds and Dr Elizabeth Rohrs, represents a clinical milestone as the world's first deployment of nasal photodisinfection within an ICU setting.

Carolyn Cross, CEO of Ondine Biomedical, stated:

"As an annual national meeting, the CACCNC provides the ideal stage to introduce Ondine's nasal photodisinfection protocol to nursing leaders who are instrumental in implementing new safety standards across Canada's provincial health authorities. With a focus on 'improving outcomes for the most vulnerable', the conference highlights the critical role of nursing-led interventions in reducing healthcare-associated infections. The selection of the Steriwave study for oral presentation underscores the conference's commitment to spotlighting disruptive technologies that address the growing challenge of antimicrobial resistance in the ICU."

The study, recently published in the Journal of Critical Care, investigated the efficacy of Ondine's Steriwave nasal photodisinfection therapy, a non-antibiotic technology already demonstrated to reduce SSIs in Canadian and UK hospitals, within the high-stakes environment of critical care.

Key findings include:

· Substantial Decrease in Pneumonia: Top-line results demonstrated a 39.5% reduction in pneumonia rates, falling from 14.9 to 9.0 cases per 1,000 ICU patient-days.

· Significant Pathogen Reduction: The intervention achieved a statistically significant reduction in early cumulative nasal pathogen burden (p < 0.01).

· Safety Demonstrated: No intervention-related adverse events were detected.

The study builds on established evidence supporting nasal decolonisation as a strategy to reduce ICU infection rates, laying a strong foundation for larger follow-on trials with the potential to inform future standards of care in pneumonia prevention.

 

Ondine Biomedical Inc.
www.ondinebio.com
Carolyn Cross, CEO
+1 604 669 0555
 or via 5654 & Company
Strand Hanson Limited (Nominated Adviser & Joint Financial Adviser)
James Harris, Richard Johnson
+44 (0)20 7409 3494
Peel Hunt LLP (Joint Bookrunner and Broker, Joint Financial Adviser)
James Steel,Sohail Akbar
+44 (0)20 7418 8900
5654 & Company (Financial PR and IR Adviser)
ondinebiomedical@5654.co.uk
Matthew Neal, Chris Gardner, Melissa Gardiner
+44 0791 7800 011
 +44 0775 7697 357

Enquiries

About the CACCNC

The Canadian Critical Care Nursing Conference (CACCNC), hosted by the Canadian Association of Critical Care Nurses, is the premier annual national conference for critical care nursing in Canada. It brings together nurses, educators, researchers and interprofessional clinicians to share evidence-based practice, research and innovation in the care of critically ill patients. The conference provides a forum for the dissemination of new research, the evaluation of evolving clinical practices and the discussion of emerging approaches to patient care, supporting collaboration and knowledge exchange across the Canadian critical care community.

About Steriwave® and its Mode of Action

Steriwave nasal photodisinfection is a non-invasive and painless treatment that uses a proprietary light-activated photosensitive agent to destroy harmful bacteria, viruses, and fungi-including antibiotic-resistant strains-in the nasal passages. The procedure takes five minutes and, unlike antibiotics, is effective immediately and allows the normal nasal microbiome to recover quickly, without fostering antimicrobial resistance.

The two-step process involves applying the Steriwave formulation in the nostrils where it electrostatically binds to microbes rather than human cells. The area is then illuminated with safe red light to activate the formulation, triggering an oxidative burst that physically destroys all manner of pathogens within minutes. This rapid and overwhelming oxidative stress makes it extremely difficult for pathogens to develop resistance, and the process stops immediately once the light is turned off. Steriwave has been used in a growing number of Canadian hospitals since 2011.

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's Steriwave photodisinfection system has a CE mark in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAMZGZDNVMGVZM